Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Janssen to Sell Tapenta License to Mundipharma in Japan
July 25, 2017
- Positive Top-Line Data Out for Shionogi’s Sakigake-Designated Flu Med
July 25, 2017
- Boehringer Japan, Kyoto Univ. Seal 2-Year COPD Pact
July 25, 2017
- Novartis Wants to Deliver CAR-T Therapy to Japanese Patients ASAP: Exec
July 25, 2017
- Novartis Japan Revenue Nearly Hit Bottom, FY2016 Sales Down 3.7%: New Chief
July 25, 2017
- (Update) Mitsubishi Tanabe to Buy Israel’s NeuroDerm for US$1.1 Billion
July 25, 2017
- Ono Focuses on Combination Therapy of Opdivo with Chemotherapies; Development of Small-Molecule Drugs also Underway
July 25, 2017
- Mitsubishi Tanabe to Buy Israel’s NeuroDerm for US$1.1 Billion
July 24, 2017
- Gilteritinib Earns US Orphan Status for AML: Astellas
July 24, 2017
- Hemophilia A Treatment Emicizumab Filed in Japan: Chugai
July 24, 2017
- Takeda, Schrödinger Link Up on Drug Discovery
July 24, 2017
- Asahi Kasei Pharma to Expand Lineup in Orthopedic Field, Boost Osteoporosis Market Share through Once-Yearly Formulation of Reclast
July 24, 2017
- AZ Japan Facing Civil Lawsuit over Demotions, Pay Cuts
July 21, 2017
- Whistleblower Bayer Rep Raps “No Instruction” Finding in Xarelto Scandal Probe
July 21, 2017
- Takecab Most Promoted Drug for Hospital Doctors for 7th Month: Anterio
July 21, 2017
- NanoCarrier’s Micellar Nanoparticle Drug Gets FDA Orphan Status
July 20, 2017
- Kowa President Has High Hopes for Livalo Successor Parmodia
July 20, 2017
- Zymeworks Gains US$1 Million from Daiichi Sankyo in Bispecific Antibody Milestone
July 20, 2017
- Hisamitsu Begins New Japan PIII for NSAIDs Patch after Unfavorable PII/III
July 20, 2017
- Takeda-Teva JV to Discontinue Sale of 53 Generic APIs
July 19, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…